Clinical trial
A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)
NCT00701181 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)
- Lead sponsor
- Quark Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 30, 2008
- Completion date
- January 31, 2011
- Enrollment
- 184 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.